英國研發(fā)貼片新冠疫苗

Oxfordshire-based company Emergex will soon start clinical trials of a second-generation vaccine against COVID-19, an easy-to-administer skin patch that uses T-cells to kill infected cells and could offer longer-lasting immunity than current vaccines. The vaccine will eventually be administered as a skin patch the size of a thumbnail bristling with micro-needles that release the shot within seconds.

英國牛津郡的Emergex公司將針對第二代新冠疫苗開展臨床試驗(yàn)。Emergex公司的這款疫苗利用T細(xì)胞殺死被感染的細(xì)胞，最終將以"拇指大小的皮膚貼片"形式接種，易于注射，且可以提供比現(xiàn)有疫苗更持久的免疫力。當(dāng)貼片接觸皮膚時(shí)，上面的微型針頭在幾秒內(nèi)就會把疫苗注入體內(nèi)。

It can last for up to three months at room temperature, unlike other jabs that need to be stored in the freezer or fridge.

貼片疫苗與其他需存放在低溫環(huán)境中的新冠疫苗不同，可以在室溫下保存長達(dá)3個(gè)月。

Emergex has received the green light from the Swiss drugs regulator to conduct initial human trials in Lausanne starting on Jan 3.

Emergex公司已獲得瑞士藥品監(jiān)管機(jī)構(gòu)的批準(zhǔn)，并將于明年1月3日開始在洛桑開展初期臨床試驗(yàn)。

Interim results from the trial are expected in June.

試驗(yàn)的中期結(jié)果預(yù)計(jì)將于6月公布。